Alex C. Sapir is the President and Chief Executive Officer at Fulcrum Therapeutics Inc., a biotechnology company focused on improving the lives of patients with genetically defined rare diseases. With a strong background in the biopharmaceutical industry, Sapir has demonstrated exceptional leadership and strategic vision throughout his career. Prior to joining Fulcrum Therapeutics, he held various leadership positions at companies such as Biogen, where he served as the Senior Vice President and Head of the Rare Disease Unit, and Alexion Pharmaceuticals, where he was the Senior Vice President and Global Head of R&D Operations. At Fulcrum Therapeutics, Sapir has been instrumental in advancing the company's mission to develop transformative therapies for rare genetic disorders. Under his guidance, the company has made significant progress in its clinical programs, particularly with the development of losmapimod, a potential treatment for facioscapulohumeral muscular dystrophy (FSHD). Sapir's strategic leadership has also been crucial in securing partnerships and collaborations that have further strengthened Fulcrum's position in the rare disease space. His ability to navigate the complex landscape of drug development and his commitment to patient-centric innovation have been key drivers of the company's success. In addition to his role at Fulcrum Therapeutics, Sapir is recognized for his contributions to the broader biotechnology community. He has been an advocate for rare disease research and has participated in numerous industry conferences and panels, sharing his insights on the challenges and opportunities in developing therapies for underserved patient populations. Sapir's dedication to advancing scientific discovery and his passion for improving patient outcomes continue to shape his leadership at Fulcrum Therapeutics and beyond.